🎙️ In this episode, Dr. Ángela Lamarca, from Fundación Jiménez Díaz, provides a comprehensive overview of the major advances in hepatobiliary–pancreatic and neuroendocrine tumors throughout 2025 and reflects on the challenges and expectations that will shape 2026.

In hepatocellular carcinoma, emphasis is placed on data in intermediate-stage disease supporting the combination of systemic therapies with locoregional treatments, in contrast to the negative results observed in the adjuvant setting following surgery or ablation. Looking ahead to 2026, improved definition of subgroups within the intermediate stage and the development of neoadjuvant strategies are anticipated.

In neuroendocrine tumors, advances in radionuclide therapies during 2025 are reviewed, including their use without somatostatin analogues. Particular attention is given to the ongoing NETTER-3 trial, which will evaluate the role of these therapies in the first-line setting.

In pancreatic adenocarcinoma, progress in targeted therapies is discussed, especially KRAS and PRMT5 inhibitors, with a particular focus on MTAP-altered tumors. There is an expectation that 2026 will consolidate precision medicine approaches and provide new data in first-line treatment.

Finally, in biliary tract cancers, the consolidation of targeted therapies is analyzed, along with the key role of next-generation sequencing (NGS) in identifying actionable alterations, as well as first-line clinical trials that will be developed during 2026.

-------------------------------

The purpose of this podcast is to provide continuing medical education and information for healthcare professionals.

It is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of specific cases.

The participants express their own opinions, experiences, and conclusions.